You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Tuesday, December 5, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

       

       

      CME / ABIM MOC

      LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

      • Authors: Charles H. Yoon, PhD, MD, FACS; Inderjit Mehmi, MD; Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC
      • CME / ABIM MOC Released: 11/16/2023
      • Valid for credit through: 11/16/2024, 11:59 PM EST
      Start Activity

      • Credits Available

        Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

        ABIM Diplomates - maximum of 1.00 ABIM MOC points

        You Are Eligible For

        • Letter of Completion
        • ABIM MOC points

      Target Audience and Goal Statement

      This activity is intended for oncologists, dermatologists, surgeons, pathologists, and other clinicians involved in the care of patients with metastatic melanoma.

      The goal of this activity is for learners to better understand the role of the multidisciplinary team (MDT) in the optimal care of patients receiving LAG-3 inhibitor-containing regimens for metastatic melanoma.

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • LAG-3 inhibitor-containing regimens used for the treatment of metastatic melanoma
      • Have greater competence related to
        • Determining patient eligibility for LAG-3 inhibitor-containing regimens in metastatic melanoma
        • Creating personalized care plans for patients with metastatic melanoma as part of the MDT
      • Demonstrate greater confidence in their ability to
        • Engage patients with metastatic melanoma in shared decision-making for treatment considerations

      Disclosures

      Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

      Faculty

      • Charles H. Yoon, PhD, MD, FACS

        Director of Surgery for Cutaneous Oncology and Melanoma
        Dana Farber Cancer Institute
        Director of Surgical Oncology
        Merkel Cell Carcinoma Center of Excellence
        Associate Surgeon
        Surgical Oncology
        Brigham and Women's Hospital
        Assistant Professor of Surgery
        Harvard Medical School
        Boston, Massachusetts

        Disclosures

        Charles H. Yoon, PhD, MD, FACS, has no relevant financial relationships.

      • Inderjit Mehmi, MD

        Medical Oncologist
        Hematology Oncology
        Cedars-Sinai The Angeles Clinic and Research Institute
        Los Angeles, California

        Disclosures

        Inderjit Mehmi, MD, has the following relevant financial relationships:
        Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Immunocore
        Owns stock (publicly traded) in: Delcath; Ideaya; Immunocore; In8Bio

      • Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC

        Melanoma/Cutaneous Oncology and Phase 1 Research
        New York University Langone Perlmutter Cancer Center
        New York, New York

        Disclosures

        Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC, has no relevant financial relationships.

      Editors

      • Davecia R. Cameron, MS

        Medical Education Director, Medscape, LLC

        Disclosures

        Davecia R. Cameron, MS, has no relevant financial relationships.

      • Jason Luis Quiñones, PhD

        Associate Medical Writer, Medscape, LLC

        Disclosures

        Jason Luis Quiñones, PhD, has no relevant financial relationships.

      Compliance Reviewer

      • Leigh Schmidt, MSN, RN, CNE, CHCP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

      SITC Course Director

      • Dirk Schadendorf, MD

        Director & Chair
        Department of Dermatology
        Director
        Comprehensive Cancer Center (Westdeutsches Tumorzentrum)
        University Hospital Essen & Research Alliance Ruhr
        Founding Director
        Research Center One Health
        University Duisburg-Essen
        Essen, Germany

        Disclosures

        Dirk Schadendorf, MD, has the following relevant financial relationships:
        Consultant or advisor for: 4SC; Agenus; Astra Zeneca; BioAlta; Bristol Myers Squibb Company; Curevac; Daiichi Sankyo, Inc.; Erasca; Haystack; Hexal; Immatics; Immunocore; InFlarX; Merck-Serono; Merck Sharp & Dohme; Neracare; Novartis; NovoGenix; PamGene; Philogen; Pierre Fabre; Pfizer, Inc.; Regeneron; Replimune; Roche; Sanofi; Seagen, Inc.; Sun Pharma; UltimoVacs
        Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Merck-Serono; Merck Sharp & Dohme; Neracare
        Research funding from: Amgen, Inc., Bristol Myers Squibb Company; Merck Sharp & Dohme; Novartis; Roche

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements

      Developed through a partnership between Medscape and SITC.

      Medscape

      Interprofessional Continuing Education

      In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer (SITC). Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        For Physicians

      • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

        College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as noncertified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

        Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's “CME in Support of MOC” program in Section 3 of the Royal College's MOC Program.

        Contact This Provider

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

      Follow these steps to earn CME/CE credit*:

      1. Read about the target audience, learning objectives, and author disclosures.
      2. Study the educational content online or print it out.
      3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

      *The credit that you receive is based on your user profile.

      From Medscape Education Oncology
      CME / ABIM MOC

      LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

      Authors: Charles H. Yoon, PhD, MD, FACS; Inderjit Mehmi, MD; Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BCFaculty and Disclosures

      CME / ABIM MOC Released: 11/16/2023

      Valid for credit through: 11/16/2024, 11:59 PM EST

      processing....

      References

      1. Tyrell R, et al. Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma Manag. 2017;4:61-68.
      2. National Comprehensive Cancer Network (NCCN). Melanoma: Cutaneous (Version 2.2023). February 4, 2023. Accessed October 3, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
      3. Keung EZ, et al. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18:775-784.
      4. Sullivan RJ, et al. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018;6:44.
      5. Yushak M, et al. Systemic therapy options for patients with unresectable melanoma. Am Soc Clin Oncol Educ Book. 2017;37:661-672.
      6. Knight A, et al. Immunotherapy in melanoma: recent advances and future directions. Cancers (Basel). 2023;15:1106.
      7. Wolchok JD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127-137.
      8. Bello DM, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol. 2020;27:1180-1188.
      9. Nevala WK, et al. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15:1931-1939.
      10. Switzer B, et al. Evolving management of stage IV melanoma. Am Soc Clin Oncol Educ Book. 2023;43:e397478.
      11. Nivolumab and relatlimab [prescribing information]. Approved 2022. Revised March 2022.
      12. Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. Correction in: J Hematol Oncol. 2023 Sep 29;16:105. J Hematol Oncol. 2023;16:101.
      13. Switzer B, et al. Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract. 2022;18:335-351.
      14. Amado A, et al. Updates in pharmacotherapy for melanoma. US Pharm. 2018;43:HS2-HS8.
      15. National Comprehensive Cancer Network (NCCN). Management of Immunotherapy-Related Toxicities (Version 2.2023). 2023. Accessed October 3, 2023. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
      16. O'Donnell JS, et al. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25:5743-5751.
      17. Eggermont AMM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Correction in: Lancet Oncol. 2015 Jun;16:e262. Correction in: Lancet Oncol. 2016 Jun;17:e223. Lancet Oncol. 2015;16:522-530.
      18. Weber J, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
      19. Eggermont AMM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
      20. Ascierto PA, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Correction in: Lancet Oncol. 2021 Oct;22:e428. Lancet Oncol. 2020;21:1465-1477.
      21. Eggermont AMM, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J Clin Oncol. 2020;38:3925-3936.
      22. Blank CU, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655-1661.
      23. Rozeman EA, et al. Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses. J Clin Oncol. 2017;35(15 suppl):9586.
      24. Versluis JM, et al. Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: the OpACIN and OpACIN-neo trials. J Clin Oncol. 2023;34:420-430.
      25. Reijers ILM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178-1188.
      26. ClinicalTrials.gov. A study to compare the administration of pembrolizumab after surgery versus administration both before and after surgery for high-risk melanoma. NCT03698019. Updated May 3, 2023. Accessed October 30, 2023. https://clinicaltrials.gov/study/NCT03698019
      27. Patel SP, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813-823.
      28. Amaria RN, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611:155-174.
      29. Hieken TJ, et al. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023;43:e390614.
      30. Holder AM, et al. Timing is everything: neoadjuvant versus adjuvant immunotherapy in patients with resectable metastatic melanoma. Correction in: Ann Surg Oncol. 2023 Nov;30:7688. Ann Surg Oncol. 2023;30:6953-6957.
      31. Amaria RN, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [published correction appears in Nat Med. 2018 Oct 25] [published correction appears in Nat Med. 2018 Oct 25]. Nat Med. 2018;24:1649-1654.
      32. Liu J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8:e1581530.
      33. Amaria RN, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20:e378-e389.
      34. Mott NM, et al. Implementation of melanoma guidelines in the multidisciplinary setting: a qualitative analysis. Am J Surg. 2023;225:335-340.
      35. Cornelius LA, et al. Multidisciplinary care of BRAF-mutant stage III melanoma: a physicians perspective review. Oncologist. 2021;26:e1644-e1651.
      36. Puza CJ, et al. The emerging role of surgery for patients with advanced melanoma treated with immunotherapy. J Surg Res. 2019;236:209-215.
      37. Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435.
      38. ClinicalTrials.gov. A phase II study of the interleukin-6 receptor inhibitor tocilizumab in combination with ipilimumab and nivolumab in patients with unresectable stage III and stage IV melanoma. Updated January 26, 2023. Accessed October 3, 2023. https://www.clinicaltrials.gov/study/NCT03999749
      39. ClinicalTrials.gov. A phase II/III trial of nivolumab, ipilimumab, and GM-CSF in patients with advanced melanoma. NCT02339571. Updated October 27, 2023. Accessed October 3, 2023. https://clinicaltrials.gov/study/NCT02339571
      40. Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34.
      41. Ibrahim R, et al. LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy. Biomedicines. 2023;11:1878.
      42. Khushalani NI, et al. Current challenges in access to melanoma care: a multidisciplinary perspective. Am Soc Clin Oncol Educ Book. 2021;41:e295-e303.
      43. Silva IPD, et al. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer. 2020;126:86-97.
      44. Rauwerdink DJW, et al. Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg Oncol. 2020;27:3488-3497.
      45. Bedikian AY, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-4745.
      46. Middleton MR, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Correction in: J Clin Oncol. 2000 Jun;18:2351. J Clin Oncol. 2000;18:158-166.
      47. Korn EL, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
      48. Wolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. Correction in: N Engl J Med. 2018 Nov 29;379:2185. N Engl J Med. 2017;377:1345-1356.
      49. Wolchok JD, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15 suppl):9506.
      50. Steininger J, et al. Systemic therapy of metastatic melanoma: on the road to cure. Cancers (Basel). 2021;13:1430.
      51. Pembrolizumab [prescribing information]. Approved 2014. Revised August 2023.
      52. Atezolizumab [prescribing information]. Approved 2016. Revised May 2023.
      53. Ipilimumab [prescribing information]. Approved 2011. Revised February 2023.
      54. Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. Correction in: N Engl J Med. 2018 Nov 29;379:2185. N Engl J Med. 2015;373:23-34.
      55. Eggermont AM, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. Correction in: N Engl J Med. 2018 Nov 29;379:2185. N Engl J Med. 2016;375:1845-1855.
      56. Long GV, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202-1210.
      57. Andrews LP, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80-96.
      58. Huo JL, et al. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090.
      59. Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. Correction in: J Hematol Oncol. 2023 Sep 29;16:105. J Hematol Oncol. 2023;16:101.
      60. Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917-927.
      61. Kreidieh FY, et al. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol. 2023;15:17588359231186027.
      62. Tawbi HA, et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. J Clin Oncol. 2023;41(16 suppl):9502.
      63. Hamid O, et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: post adjuvant PD-1 analysis. J Clin Oncol. 2023;41(16 suppl):9501.
      64. Seth R, et al. Systemic therapy for melanoma: ASCO guideline. Correction in: J Clin Oncol. 2023 Sep 18;JCO2301773. J Clin Oncol. 2020;38:3947-3970.
      65. Ascierto PA, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. J Clin Oncol. 2023;41:2724-2735.
      66. VanderWalde A, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29:2278-2285.
      67. Baramidze A, et al. A phase 3 trial of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. J Clin Oncol. 2023;41:TPS9602.
      68. ClinicalTrials.gov. Substudy 02A: safety and efficacy of pembrolizumab in combination with investigational agents in participants with programmed cell-death 1 (PD-1) refractory melanoma (MK-3475-02A/KEYMAKER-U02). Updated September 5, 2023. Accessed October 11, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04305041
      69. ClinicalTrials.gov. A study of multiple doses of RO7247669 in participants with previously untreated unresectable or metastatic melanoma. Updated October 5, 2023. Accessed October 11, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05419388
      70. ClinicalTrials.gov. XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in treating melanoma prior immune checkpoint inhibitor therapy. Updated August 24, 2023. Accessed October 11, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05695898
      71. ClinicalTrials.gov. Study of combination therapy with INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in participants with select advanced malignancies. Updated October 23, 2023. Accessed October 11, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04370704
      72. Cancer.net. Melanoma: types of treatment. Published February 2023. Accessed October 11, 2023. https://www.cancer.net/cancer-types/melanoma/types-treatment
      73. Tagliaferri L, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2022;18:1903827.
      74. Kodet O, et al. The abscopal effect in the era of checkpoint inhibitors. Int J Mol Sci. 2021;22:7204.
      75. Rogan SA, et al. Sentinel lymph node concept and its role in the management of melanoma patients. Acta Clin Croat. 2007;46:175.
      76. Muthiah S, et al. A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma. Br J Dermatol. 2018;178:1-4.
      77. National Cancer Institute (NCI). T-cell transfer therapy. Updated April 1, 2022. Accessed October 11, 2023. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy
      78. Khushalani NI, et al. Current challenges in access to melanoma care: a multidisciplinary perspective. Am Soc Clin Oncol Educ Book. 2021;41:e295-e303.
      79. Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387:2113-2125.
      80. Betof-Warner A, et al. Adoptive cell transfer and vaccines in melanoma: the horizon comes into view. Am Soc Clin Oncol Educ Book. 2022;42:1-8.
      81. Advanced Practitioners in Oncology (APSHO). Advanced practitioners in oncology: meeting the challenges. Accessed October 11, 2023. https://www.apsho.org/page/AbouttheAP/Advanced-Practitioners-in-Oncology-Meeting-the-Challenges.htm
      82. Rubin KM. Advances in melanoma: the rationale for the Melanoma Nursing Initiative. Clin J Oncol Nurs. 2017;21(4 suppl):7-10.
      83. Wood LS, et al. Immune checkpoint inhibitor therapy: key principles when educating patients. Clin J Oncol Nurs. 2019;23:271-280.
      84. Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
      85. Watson AS, et al. Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy. JAMA Netw Open. 2022;5:e2245596.
      86. Wiley K, et al. Immunotherapy administration: Oncology Nursing Society recommendations. Clin J Oncol Nurs. 2017;21:5-7.
      87. Haanen J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217-1238.
      88. Fee-Schroeder K, et al. Empowering individuals to self-manage chemotherapy side effects. Clin J Oncol Nurs. 2013;17:369-371.
      89. Fradkin M, et al. Leveraging technology to optimize the care of patients treated with immunotherapy. Presented at: the 42nd ONS Annual Congress. May 4, 2017; Denver, CO. Abstract 31.
      90. Fecher LA, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18:733-743.
      91. Shao K, et al. Racial and ethnic healthcare disparities in skin cancer in the United States: a review of existing inequities, contributing factors, and potential solutions. J Clin Aesthet Dermatol. 2022;15:16-22.
      92. Dellson P, et al. Patients' reasoning regarding the decision to participate in clinical cancer trials: an interview study. Trials. 2018;19:528.
      93. Steinberg H. Oncology nurse coordinators in clinical trials - shaking up the melanoma team. Asia Pac J Oncol Nurs. 2020;7:250-254.
      94. Grady C, et al. Science, technology, and innovation: nursing responsibilities in clinical research. Nurs Clin North Am. 2009;44:471-481.
      95. Karam S. Nursing roles in clinical trials. ONS Voice. December 7, 2021. Accessed October 11, 2023. https://voice.ons.org/news-and-views/nursing-roles-in-clinical-trials
      96. Rubin K. Management of metastatic melanoma: nursing challenges today and tomorrow. Clin J Oncol Nurs. 2009;13:81-89.
      97. Kirkwood JM, et al. Collaborative care in melanoma: the essential role of the nurse. Clin J Oncol Nurs. 2017;21:4-6.
      98. Mott NM, et al. Implementation of melanoma guidelines in the multidisciplinary setting: a qualitative analysis. Am J Surg. 2023;22:335-340.
      99. Wouters MW, et al. ECCO essential requirements for quality cancer care: melanoma. Crit Rev Oncol Hematol. 2018;122:164-178.
      100. Milne D, et al. Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: "real-world" data. Cancer Nurs. 2020;43:E97-E104.
      101. Boyle DA. Psychological adjustment to the melanoma experience. Sem Oncol Nurs. 2003;19:70-77.
      102. Lai-Kwon, et al. Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT). J Clin Oncol. 2018;36:e21503.
      103. Lai-Kwon J, et al. Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE). Support Care Cancer. 2022;30:9587-9596.
      104. Wiley K. Nursing considerations for melanoma survivorship care. ONS Voice. May 13, 2021. Accessed October 11, 2023. https://voice.ons.org/news-and-views/nursing-considerations-for-melanoma-survivorship-care
      « Return to: LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team
      CME / ABIM MOC Information
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.